<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154034">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01094691</url>
  </required_header>
  <id_info>
    <org_study_id>08-1519</org_study_id>
    <nct_id>NCT01094691</nct_id>
  </id_info>
  <brief_title>Haufen Diagnostic Biomarkers of BK Renal Disease</brief_title>
  <official_title>Polyomavirus Aggregates, Haufen, in Voided Urine Samples as Diagnostic Biomarkers of Intra Renal BK-virus Disease: a Prospective Proof-of-concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To prospectively test whether the detection of three-dimensional, cast-like polyomavirus
      aggregates, termed Haufen, in voided urine samples can serve as an accurate biomarker of
      intra-renal disease, i.e. polyoma-BK-virus nephropathy (PVN). We want to correlate the
      detection of 'Haufen' with histologic findings made in renal biopsies as well as signs of
      polyomavirus activation, i.e. viremia and viruria. The prospective study is designed to
      further validate our retrospective findings (manuscript in press, J Am Soc Nephrology) and
      more specifically to correlate 'Haufen' shedding with the histologically confirmed course of
      PVN.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlate Haufen, urine and plasma data with the clinical presentation and - in selected cases - with renal biopsy findings.</measure>
    <time_frame>The biopsy will be performed when urine is determined to be Haufen negative</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Polyoma Virus Nephropathy</condition>
  <arm_group>
    <arm_group_label>Renal Allograft Biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Renal Allograft Biopsy</intervention_name>
    <description>A renal allograft biopsy will be performed when the urine is determined to be Haufen negative.</description>
    <arm_group_label>Renal Allograft Biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Recipient of renal transplant

          -  Positive for polyoma virus

          -  Haufen cells present in urine

          -  Positive for polyoma virus nephropathy

        Exclusion Criteria:

          -  anyone who does not meet the inclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Nickeleit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina-CH Dept of Pathology</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 14, 2016</lastchanged_date>
  <firstreceived_date>March 25, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Volker Nickeleit, MD</investigator_full_name>
    <investigator_title>Director of the UNC Division of Nephropathology</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
